Article

FDA Briefs - March 1, 2002

Allergan's brimonidine tartrate (Alphagan) will have new labeling that indicates its 0.5% strength is suitable for pediatric patients over 2 years old.

Related Videos
J. Peter Campbell, MD, MPH
Expanding accessibility of vision correction with spectacles for children with cranial abnormalities
Elkin: Talking about the importance of pediatric eye health and safety
Identifying 3 barriers keeping families from accessing cataract treatment for their children in India
Edward Manche, MD
Related Content
NIH highlights 5 key elements of cortical visual impairment (CVI)
November 23rd 2024

NIH highlights 5 key elements of cortical visual impairment (CVI)

ROP: Treating and preventing blindness in preterm babies
October 18th 2021

ROP: Treating and preventing blindness in preterm babies

Cerebral visual impairment is a growing concern in pediatric vision loss
November 14th 2024

Cerebral visual impairment is a growing concern in pediatric vision loss

Managing a changing landscape of IRD pediatric cases
May 10th 2021

Managing a changing landscape of IRD pediatric cases

FDA grants fast track status to FELIQS’ FLQ-101 for ROP
November 6th 2024

FDA grants fast track status to FELIQS’ FLQ-101 for ROP

Cerebral visual impairment: A growing concern in pediatric vision loss
October 30th 2024

Cerebral visual impairment: A growing concern in pediatric vision loss

© 2024 MJH Life Sciences

All rights reserved.